The NeurologyLive® stroke clinical focus page serves as a resource for updates and information related to the clinical care and management of stroke and cerebrovascular disease, featuring news, podcasts, and videos about the latest FDA actions, clinical guideline updates, interviews with physicians, and study and clinical trial findings. The page includes information on stroke, large vessel occlusion, subcranial hemorrhage, intracranial hemorrhage, ischemic stroke, and more.
August 20th 2025
At AHS 2025, Elizabeth Seng, PhD, professor of neurology at Albert Einstein College of Medicine, presented findings from a study showing that migraine was associated with increased odds of ischemic stroke in veterans.
Zoom Stroke Solution Shows Continued Efficacy in Treating Distal Occlusions of Ischemic Stroke
August 27th 2022For patients with MCA M2 occlusions, use of the Zoom Stroke Solution resulted in significant decreases in National Institutes of Health Stroke Scale scores and no reported perforations or other reperfusion–catheter-related complications.
Remote Ischemic Conditioning Improves Likelihood of Excellent Outcomes in Post Stroke
August 25th 2022Treatment with remote ischemic conditioning performed twice daily for 2 weeks as an adjunct to guideline-based treatment resulted in higher odds of modified Rankin Scale scores between 0 and 1, and 0 and 2.
Chronic Kidney Disease Associated With Increased Risk of Intracerebral Hemorrhage
August 19th 2022Mendelian randomization analyses identified a significant association between genetically determined chronic kidney disease and intracerebral hemorrhage risk, supporting a causal association between the 2 conditions.
Trends in Stroke Incidence for Younger Ages Prompt Need to Reexamine Causes, Prevention Methods
August 12th 2022When combing all 26 studies irrespective of methods, the lowest age-specific divergence in incidence was seen in 3 Southern European studies, and the most pronounced divergence in North American studies.
Alnylam Reports Positive Data on Patisiran in APOLLO-B Trial of ATTR Amyloidosis With Cardiomyopathy
August 4th 2022The Alnylam Pharmaceuticals agent, already approved for the treatment of polyneuropathy in those with hATTR amyloidosis, has now shown promise as a therapeutic option for patients with ATTR amyloidosis with cardiomyopathy.